Yuandong Biology (688513.SH): Nicadipine hydrochloride injections and other drugs to be selected for centralized procurement across the country

Zhitongcaijing · 1d ago

Zhitong Finance App News, Yuandong Biotech (688513.SH) announced that the company and its wholly-owned subsidiary Chengdu Shuode Pharmaceutical Co., Ltd. participated in the bidding process for the 12th batch of centralized national drug procurement organized by the Joint Procurement Office of the State Organization on July 31, 2026. According to the “Announcement on the Proposed Selection Results for the 12th Batch of Centralized Volume Procurement of National Organization Drugs” issued by the Joint Procurement Office that night, the company and its wholly-owned subsidiaries plan to select nicardipine hydrochloride injections and bisoprolol amlodipine tablets for this centralized procurement.

The centralized procurement cycle is from the actual execution date of the selection results to December 31, 2029. In the procurement cycle, medical institutions will prioritize the use of selected drugs from this centralized procurement and ensure completion of the agreed procurement volume. It is expected that implementation will begin in the fourth quarter of 2026, and there will be no impact on the company's business performance for the first half year of 2026. The selected price has decreased to a certain extent compared to the original sales price. If the company subsequently signs and executes a procurement contract, it will help further expand sales of related products, expand cooperation channels, promote the development of domestic markets for related products, and enhance the accessibility of pharmaceuticals.